Constance Sweet, MD
Family Medicine · Towanda, PANPI 1134103666
Payments from drug & device makers
Across 536 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- Amgen$1K
- Pfizer$480
- AstraZeneca$408
- Boehringer Ingelheim$399
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,305100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 112 | $1,646 |
| Lilly USA, LLC | 92 | $1,445 |
| Amgen | 70 | $1,049 |
| Pfizer | 39 | $480 |
| AstraZeneca | 22 | $408 |
| Boehringer Ingelheim | 24 | $399 |
| GSK | 21 | $350 |
| Sanofi-aventis U.S. LLC | 20 | $318 |
| Otsuka America Pharmaceutical, Inc. | 14 | $245 |
| Axsome Therapeutics, Inc. | 7 | $196 |
| Teva Pharmaceuticals USA, Inc. | 11 | $175 |
| Paratek Pharmaceuticals, Inc. | 10 | $148 |
| Merck | 9 | $129 |
| E.r. Squibb & Sons, L.L.C. | 8 | $127 |
| Grifols USA, LLC | 7 | $126 |
| Astellas Pharma US Inc | 8 | $109 |
| Amarin Pharma, Inc. | 7 | $101 |
| Novo Nordisk | 6 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Biohaven Pharmaceuticals, Inc. | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $70 |
| Dexcom, Inc. | 5 | $70 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Novartis | 4 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| Lundbeck LLC | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Indivior Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Organon | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $13 |
How this compares
$8,317 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $116,181 |
| TrulicityDulaglutide | 58 | $75,371 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $72,605 |
| MounjaroTirzepatide | 57 | $69,863 |
| JardianceEmpagliflozin | 66 | $63,117 |
| OzempicSemaglutide | 37 | $48,978 |
| FarxigaDapagliflozin Propanediol | 41 | $39,261 |
| ZenpepLipase/Protease/Amylase | 12 | $36,629 |
| RexultiBrexpiprazole | 16 | $32,905 |
| JanuviaSitagliptin Phosphate | 30 | $31,023 |
| OxycontinOxycodone Hcl | 25 | $28,202 |
| VraylarCariprazine Hcl | 18 | $27,995 |
| Emgality SyringeGalcanezumab-Gnlm | 24 | $27,768 |
| RybelsusSemaglutide | 20 | $19,707 |
| XareltoRivaroxaban | 20 | $17,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,445 | $145,234115 claims |
| PfizerEliquis | $480 | $116,181136 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $399 | $89,915117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $350 | $87,931139 claims |
| Novo NordiskOzempic, Rybelsus | $90 | $68,68557 claims |
| MerckJanuvia, Belsomra | $129 | $39,87151 claims |
| AstraZenecaFarxiga | $408 | $39,26141 claims |
| AbbVieVraylar, Linzess | $1,646 | $39,05533 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $245 | $32,90516 claims |
| Johnson & JohnsonXarelto, Invokana | $28 | $23,58031 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $85 | $16,59114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Towanda
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.